Prostate-specific antigen kinetics after primary stereotactic body radiation therapy using CyberKnife for localized prostate cancer.

To assess prostate-specific antigen (PSA) kinetics and report on the oncologic outcomes for patients with localized prostate cancer treated with stereotactic body radiation therapy (SBRT) using CyberKnife.

We extracted the list and data of 39 patients with clinically localized prostate cancer who had undergone primary SBRT using CyberKnife between January 2008 and December 2012 from the Smart Prostate Cancer database system of Seoul St Mary's Hospital Changes in PSA over time, PSA velocity, and PSA nadir were evaluated from the completion of SBRT using CyberKnife Biochemical recurrence (BCR)-free survival after primary SBRT using CyberKnife was determined using Kaplan-Meier analysis

The rate of PSA decrease was maximal in the first month (median -3 34 ng/mL/mo), which then fell gradually with median values of -1 51, -0 32, -0 28, -0 20, and -0 03 ng/mL/mo for durations of 3, 6, 9, 12, and 24 months after SBRT using CyberKnife, respectively The median PSA nadir was 0 31 ng/mL after a median 23 months Kaplan-Meier analysis calculates an actuarial 5-year BCR-free survival after SBRT using CyberKnife as 80 8%

PSA decline occurred rapidly in the first month, and then the rate of PSA decline fell off steadily over time throughout 2 years after treatment Also, SBRT using CyberKnife leads to long-term favorable BCR-free survival in localized prostate cancer

Prostate international 2015 Feb 12 [Epub]

Yong Hyun Park, In Young Choi, Sei Chul Yoon, Hong Seok Jang, Hyong Woo Moon, Sung-Hoo Hong, Sae Woong Kim, Tae-Kon Hwang, Ji Youl Lee

Department of Urology, Seoul St Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea , Department of Medical Informatics, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea , Department of Radiation Oncology, Bucheon St Mary's Hospital, The Catholic University of Korea College of Medicine, Bucheon, Republic of Korea , Department of Radiation Oncology, Seoul St Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea , Department of Urology, Seoul St Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea , Department of Urology, Seoul St Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea , Department of Urology, Seoul St Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea , Department of Urology, Seoul St Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea , Department of Urology, Seoul St Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Republic of Korea

PubMed     Full Text Article

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe